Thalia Therapeutics Plc (0GO)
Market Closed
12 Aug, 06:11
XFRA XFRA Primary 
LSE €
0. 01
0
0%
€
416.14K Market Cap
- P/E Ratio
- Div Yield
225 Volume
- Eps
€ 0.01
Previous Close Want to track 0GO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
0GO closed today higher at €0.01, an increase of 0% from yesterday's close, completing a monthly increase of 60% or €0. Over the past 12 months, 0GO stock gained 700%.
0GO is not paying dividends to its shareholders.
The last earnings report, released on Sep 22, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
Thalia Therapeutics Plc (0GO) FAQ
What is the stock price today?
The current price is €0.01.
On which exchange is it traded?
Thalia Therapeutics Plc is listed on XFRA.
What is its stock symbol?
The ticker symbol is 0GO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 416.14K.
Has Thalia Therapeutics Plc ever had a stock split?
No, there has never been a stock split.
Thalia Therapeutics Plc Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. David Horn Solomon M.D. CEO | XFRA Exchange | GB00BYW8QM32 ISIN |
| United Kingdom Country | 4 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
N4 Pharma Plc is a distinguished specialist pharmaceutical company operating out of London, United Kingdom. Since its incorporation in 1979, the company has been at the forefront of developing innovative silica nanoparticle delivery systems. These advanced systems are designed to serve the pharmaceutical and biotechnology sectors within the UK, offering new possibilities in the delivery of therapeutics. N4 Pharma Plc is dedicated to revolutionizing the healthcare industry by providing cutting-edge solutions that enhance the efficacy and delivery of vaccines and cancer treatments.
Products and Services
- Nuvec - A groundbreaking non-viral adjuvant delivery system primarily aimed at enhancing the delivery of vaccines and cancer treatments. Nuvec is an innovative solution developed by N4 Pharma Plc to address the limitations of current delivery systems in the biopharmaceutical industry. By employing silica nanoparticles, Nuvec significantly improves the stability and efficiency of therapeutic delivery, ultimately leading to more effective treatment outcomes. It stands at the forefront of N4 Pharma's efforts to contribute to the advancement of medical science and patient care.
Contact Information
Address: 2 Portman Street
Phone: 44 20 4610 0714
Website: https://www.thaliatx.com
